Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oscient grants Abbott Canadian Factive rights
In exchange for those rights, Abbott Canada has agreed to a transfer price on product purchases and to make certain payments to Oscient upon achievement of certain regulatory
In exchange for those rights, Abbott Canada has agreed to a transfer price on product purchases and to make certain payments to Oscient upon achievement of certain regulatory
The proof-of-concept trial will test for analgesic activity and the safety of cannabinor (PRS-211,375), a CB2-selective synthetic cannabinoid drug candidate, in healthy subjects experiencing capsaicin-induced pain. In this
Mitsubishi Pharma extensively developed the compound, named BCI-540, for another central nervous system (CNS) indication, but suspended the program when the drug met safety expectations but did not
In the course of the collaboration, Evotec will develop assays, including those designed for high content screening, against high priority biological targets thought to be of importance in
Under the terms of the deal, Sofgen is responsible for the formulation and development of the drug, the manufacture of clinical product batches, and the documentation necessary to
In March 2006, Pharming announced a heads of agreement with DNage to acquire all shares of the biopharmaceutical company. However, during the acquisition process, the Works Council of
The phase I study is an open-label, multi-center trial designed to establish the maximum tolerated dose (MTD) for oral PXD101 administered once or twice daily. Patients will be
Protox also reported that the University of Vermont will participate in the clinical trial, joining Scott & White Memorial Hospital, the lead center in the trial, which began
The results of the five-year study, which was led by an international team that includes a researcher at Duke University Medical Center, have been published in New England
Priority review is granted to a pharmaceutical compound that addresses an unmet medical need and would be a significant improvement in treatment compared to existing therapies. The FDA